StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) stock

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.59+0.16 (+11.19%)

Close on Nov 18, 2026Market cap $41.79MP/E –Yield –

Elicio Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Elicio Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$36.97M. For fiscal 2025 it was -$36.97M. The highest annual figure on record is -$22.83M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$36.97M–
FY2024Dec 31, 2024-$37.16M–
FY2023Dec 31, 2023-$32.76M–
FY2022Dec 31, 2022-$22.83M–
FY2021Dec 31, 2021-$53.03M–
FY2020Dec 31, 2020-$22.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$6.81M–
Q3 FY2025Sep 30, 2025-$11.09M–
Q4 FY2024Dec 31, 2024-$8.79M–
Q3 FY2024Sep 30, 2024-$7.27M–
Q2 FY2024Jun 30, 2024-$8.97M–
Q1 FY2024Mar 31, 2024-$12.12M–
Q4 FY2023Dec 31, 2023-$9.90M–
Q3 FY2023Sep 30, 2023-$5.23M–
Q2 FY2023Jun 30, 2023-$9.48M-270.0%
Q1 FY2023Mar 31, 2023-$8.16M–
Q4 FY2022Dec 31, 2022-$7.37M–
Q3 FY2022Sep 30, 2022-$5.39M–
Q2 FY2022Jun 30, 2022$5.58M–
Q1 FY2022Mar 31, 2022-$15.65M–
Q4 FY2021Dec 31, 2021-$14.40M-170.0%
Q3 FY2021Sep 30, 2021-$15.26M–
Q2 FY2021Jun 30, 2021-$10.78M–
Q1 FY2021Mar 31, 2021-$12.59M–
Q4 FY2020Dec 31, 2020$20.58M–
Q3 FY2020Sep 30, 2020-$21.94M–
Q2 FY2020Jun 30, 2020-$12.81M–
Q1 FY2020Mar 31, 2020-$8.75M–

More Elicio Therapeutics figures

See a number that looks wrong?